Risk Factors for Incident Diabetic Polyneuropathy in a Cohort With Screen-Detected Type 2 Diabetes Followed for 13 Years: ADDITION-Denmark
The DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To study incident diabetic polyneuropathy (DPN) prospectively during the first 13 years after a screening-based diagnosis of type 2 diabetes and determine the associated risk factors for the development of DPN. RESEARCH DESIGN AND METHODS: We assessed DPN longitudinally in the Danish arm of the Anglo-Danish-Dutch study of Intensive Treatment of Diabetes in Primary Care (ADDITION) using the Michigan Neuropathy Screening Instrument questionnaire (MNSIQ), defining DPN with scores ≥4. Risk factors present at the diabetes diagnosis associated with the risk of incident DPN were estimated using Cox proportional hazard models adjusted for trial randomization group, sex, and age. RESULTS: Of the total cohort of 1,533 people, 1,445 completed the MNSIQ at baseline and 189 (13.1%) had DPN at baseline. The remaining 1,256 without DPN entered this study (median age 60.8 years [interquartile range 55.6; 65.6], 59% of whom were men). The cumulative incidence of DPN was 10% during 13 years of diabetes. Age (hazard ratio [HR] 1.03 [95% CI 1.00; 1.07]) (unit = 1 year), weight (HR 1.09 [95% CI 1.03; 1.16]) (unit = 5 kg), waist circumference (HR 1.14 [95% CI 1.05; 1.24]) (unit = 5 cm), BMI (HR 1.14 [95% CI 1.06; 1.23]) (unit = 2 kg/m2), log2 methylglyoxal (HR 1.45 [95% CI 1.12; 1.89]) (unit = doubling), HDL cholesterol (HR 0.82 [95% CI 0.69; 0.99]) (unit = 0.25 mmol/L), and LDL cholesterol (HR 0.92 [95% CI 0.86; 0.98]) (unit = 0.25 mmol/L) at baseline were significantly associated with the risk of incident DPN. CONCLUSIONS: This study provides further epidemiological evidence for obesity as a risk factor for DPN. Moreover, low HDL cholesterol levels and higher levels of methylglyoxal, a marker of dicarbonyl stress, are identified as risk factors for the development of DPN.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Neuropathic pain can lead to interference with daily activities, disability, psychosocial impairment, and reduced health-related QoL.547,552,562,563”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [547]
In the citing paper
“The earliest affected nerve fibers are usually the small myelinated and unmyelinated fibers; thus, the most common early symptoms are pain and dysesthesias (unpleasant sensations of burning).547,554,555”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [547]
In the citing paper
“Characteristically, the pain is burning, lancinating, tingling, or shooting (electric shock-like), with paresthesia, occurring in varying combinations, and is typically worse at night547”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [547]
In the citing paper
“However, the presence of atypical features including motor deficits greater than sensory, asymmetry of symptoms and signs, and rapid progression warrant a timely referral.547”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [547]
In the citing paper
“A combination of typical symptomatology and symmetrical distal sensory loss, or typical signs in the absence of symptoms, in a person with DM is highly suggestive of DPN and may not require additional evaluations or referral.547,565–567”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [547]
37 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Tesfaye, S., Boulton, A. J. M., Dyck, P. J., Freeman, R., Horowitz, M., Kempler, P., Lauria, G., Malik, R. A., Spallone, V., Vinik, A., et al. (2010) · Diabetes Care · doi:10.2337/dc10-1303 · Cited by 2,690
Diabetic neuropathy: A position statement by the American Diabetes Association
Pop-Busui, R., Boulton, A. J. M., Feldman, E. L., Bril, V., Freeman, R., Malik, R. A., Sosenko, J. M., & Ziegler, D. (2017) · Diabetes Care · doi:10.2337/dc16-2042 · Cited by 2,602 · cited 2×
“DPN increases the risk of chronic pain, falls, foot ulcers, and amputations; it also negatively affects the quality of life (3).”
BackgroundResultSelf-citationDyck, P. J., Kratz, K. M., Karnes, J. L., Litchy, W. J., Klein, R., Pach, J. M., Wilson, D. M., O'Brien, P. C., & Melton, L. J. (1993) · Neurology · doi:10.1212/wnl.43.4.817 · Cited by 1,482 · cited 1×
“Of these, diabetic polyneuropathy (DPN) is the most common complication (2).”
BackgroundVascular risk factors and diabetic neuropathy
Tesfaye, S., Chaturvedi, N., Eaton, S. E. M., Ward, J. D., Manes, C., Ionescu-Tirgoviste, C., Witte, D. R., & Fuller, J. H. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa032782 · Cited by 1,323
Self-citationFeldman, E. L., Stevens, M. J., Thomas, P. K., Brown, M. B., Canal, N., & Greene, D. A. (1994) · Diabetes Care · doi:10.2337/diacare.17.11.1281 · Cited by 1,293
Self-citationDiabetic neuropathy: clinical manifestations and current treatments
Callaghan, B. C., Cheng, H. T., Stables, C. L., Smith, A. L., & Feldman, E. L. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70065-0 · Cited by 1,211
Self-citationThe global burden of diabetes and its complications: an emerging pandemic
Susan van, D., Beulens, J. W. J., Yvonne T. van der, S., Grobbee, D. E., & Nealb, B. (2010) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/01.hjr.0000368191.86614.5a · Cited by 874 · cited 2×
“patients with diabetes over the course of their lives (1,4,5).”
BackgroundAdvances in the epidemiology, pathogenesis and management of diabetic peripheral neuropathy
Tesfaye, S., & Selvarajah, D. (2012) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2239 · Cited by 615 · cited 1×
“Other metabolic syndrome components such as obesity, hypertension, low HDL cholesterol, and hypertriglyceridemia are among the potential additional risk factors for the development of DPN (6,8,10).”
BackgroundEnhanced glucose control for preventing and treating diabetic neuropathy
Callaghan, B. C., Little, A. A., Feldman, E. L., & Hughes, R. A. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007543.pub2 · Cited by 584
Self-citationSymptoms and the body: taking the inferential leap
Van den Bergh, O., Witthöft, M., Petersen, S., & Brown, R. J. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.01.015 · Cited by 543 · cited 1×
“Potentially, this finding might reflect the use of the MNSIQ for diagnosing DPN, since other studies have found women to report more symptoms than men in general (28).”
Resultfor the ADVANCE Collaborative group, Zoungas, S., Woodward, M., Li, Q., Cooper, M. E., Hamet, P., Harrap, S., Heller, S., Marre, M., Patel, A., et al. (2014) · Diabetologia · doi:10.1007/s00125-014-3369-7 · Cited by 497
Bierhaus, A., Fleming, T., Stoyanov, S., Leffler, A., Babes, A., Neacsu, C., Sauer, S. K., Eberhardt, M., Schnölzer, M., Lasitschka, F., et al. (2012) · Nature Medicine · doi:10.1038/nm.2750 · Cited by 495
Self-citationHerman, W. H., Pop‐Busui, R., Braffett, B. H., Martin, C. L., Cleary, P. A., Albers, J. W., Feldman, E. L., & The DCCT/EDIC Research Group (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03644.x · Cited by 493
Self-citationGriffin, S. J., Borch-Johnsen, K., Davies, M. J., Khunti, K., Rutten, G. E., Sandbæk, A., Sharp, S. J., Simmons, R. K., van den Donk, M., Wareham, N. J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60698-3 · Cited by 462
Self-citationZiegler, D., Rathmann, W., Dickhaus, T., Meisinger, C., Mielck, A., & for the KORA Study Group (2008) · Diabetes Care · doi:10.2337/dc07-1796 · Cited by 397
Herman, W. H., Ye, W., Griffin, S. J., Simmons, R. K., Davies, M. J., Khunti, K., Rutten, G. E. H. M., Sandbaek, A., Lauritzen, T., Borch-Johnsen, K., et al. (2015) · Diabetes Care · doi:10.2337/dc14-2459 · Cited by 340
Self-citationGlucose Control and Diabetic Neuropathy: Lessons from Recent Large Clinical Trials
Ang, L., Jaiswal, M., Martin, C., & Pop-Busui, R. (2014) · Current Diabetes Reports · doi:10.1007/s11892-014-0528-7 · Cited by 303
GRuttenfor the ADDITION Study Group, Lauritzen, T., Griffin, S., Borch-Johnsen, K., Wareham, N., & Wolffenbuttel, B. (2000) · International Journal of Obesity · doi:10.1038/sj.ijo.0801420 · Cited by 249
Self-citationEpidemiology of polyneuropathy in diabetes and prediabetes
(2014) · Handbook of Clinical Neurology · doi:10.1016/b978-0-444-53480-4.00001-1 · Cited by 235 · cited 1×
“In addition, other potential risk factors are linked to DPN as well: age, cigarette smoking, and alcohol consumption are all associated with DPN (7,9).”
BackgroundPirart, J. (1977) · PubMed · Cited by 220
McLellan, A. C., Phillips, S. A., & Thornalley, P. J. (1992) · Analytical Biochemistry · doi:10.1016/s0003-2697(05)80005-3 · Cited by 220
Callaghan, B. C., Xia, R., Banerjee, M., de Rekeneire, N., Harris, T. B., Newman, A. B., Satterfield, S., Schwartz, A. V., Vinik, A. I., Feldman, E. L., et al. (2016) · Diabetes Care · doi:10.2337/dc16-0081 · Cited by 220
Self-citationAssociation Between Metabolic Syndrome Components and Polyneuropathy in an Obese Population
Callaghan, B. C., Xia, R., Reynolds, E., Banerjee, M., Rothberg, A. E., Burant, C. F., Villegas-Umana, E., Pop-Busui, R., & Feldman, E. L. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.3745 · Cited by 212 · cited 1×
“Other studies examining HDL cholesterol as a risk factor for DPN have been inconclusive, however (12,13), suggesting that further investigation isneeded.”
BackgroundSelf-citationRisk Factors and Comorbidities in Diabetic Neuropathy: An Update 2015
Papanas, N., & Ziegler, D. (2015) · The Review of Diabetic Studies · doi:10.1900/rds.2015.12.48 · Cited by 207
Brings, S., Fleming, T., Freichel, M., Muckenthaler, M., Herzig, S., & Nawroth, P. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18050984 · Cited by 204
Self-citationDavis, T. M. E., Yeap, B. B., Davis, W. A., & Bruce, D. G. (2008) · Diabetologia · doi:10.1007/s00125-007-0919-2 · Cited by 200 · cited 1×
“Alternatively, statins might protect against the development of DPN and may be acting as a confounder (29,30).”
BackgroundMethylglyoxal Activates Nociceptors through Transient Receptor Potential Channel A1 (TRPA1)
Eberhardt, M. J., Filipovic, M. R., Leffler, A., de la Roche, J., Kistner, K., Fischer, M. J., Fleming, T., Zimmermann, K., Ivanovic-Burmazovic, I., Nawroth, P. P., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.328674 · Cited by 190 · cited 2×
“nel, subfamily V, member 1 (TRPV1) (33) and subfamily A, member 1 (TRPA1) (34).”
Self-citationDiabetic neuropathy: one disease or two?
Callaghan, B. C., Hur, J., & Feldman, E. L. (2012) · Current Opinion in Neurology · doi:10.1097/wco.0b013e328357a797 · Cited by 156
Self-citationMediators of diabetic neuropathy: is hyperglycemia the only culprit?
Grisold, A., Callaghan, B. C., & Feldman, E. L. (2017) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000320 · Cited by 122
Self-citationCharles, M., Ejskjaer, N., Witte, D. R., Borch-Johnsen, K., Lauritzen, T., & Sandbaek, A. (2011) · Diabetes Care · doi:10.2337/dc11-0903 · Cited by 111
Self-citationHanewinckel, R., Drenthen, J., Ligthart, S., Dehghan, A., Franco, O. H., Hofman, A., Ikram, M. A., & van Doorn, P. A. (2016) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2016-314171 · Cited by 84 · cited 1×
“Other studies examining HDL cholesterol as a risk factor for DPN have been inconclusive, however (12,13), suggesting that further investigation isneeded.”
BackgroundShamsaldeen, Y. A., Mackenzie, L. S., Lione, L. A., & Benham, C. D. (2016) · Current Drug Metabolism · doi:10.2174/1389200217666151222155216 · Cited by 75
Sandbæk, A., Griffin, S. J., Sharp, S. J., Simmons, R. K., Borch-Johnsen, K., Rutten, G. E. H. M., van den Donk, M., Wareham, N. J., Lauritzen, T., Davies, M. J., et al. (2014) · Diabetes Care · doi:10.2337/dc13-1544 · Cited by 70
Self-citationPeripheral neuropathy is associated with insulin resistance independent of metabolic syndrome
Han, L., Ji, L., Chang, J., Wen, J., Zhao, W., Shi, H., Zhou, L., Li, Y., Hu, R., Hu, J., et al. (2015) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-015-0010-y · Cited by 64
Miranda-Diaz, A. G., Roman-Pintos, L. M., Rodriguez-Carrizalez, A. D., Troyo-Sanroman, R., Alatorre-Carranza, M. D. P., Cardona Muñoz, E. G., & Hernandez-Ojeda, J. (2014) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s65500 · Cited by 45
Methylglyoxal activates the human transient receptor potential ankyrin 1 channel
Ohkawara, S., Tanaka‐Kagawa, T., Furukawa, Y., & Jinno, H. (2012) · The Journal of Toxicological Sciences · doi:10.2131/jts.37.831 · Cited by 42 · cited 3×
“nel, subfamily V, member 1 (TRPV1) (33) and subfamily A, member 1 (TRPA1) (34).”
Hansen, C. S., Jensen, T. M., Jensen, J. S., Nawroth, P., Fleming, T., Witte, D. R., Lauritzen, T., Sandbæk, A., Charles, M., Fleischer, J., et al. (2015) · Diabetic Medicine · doi:10.1111/dme.12753 · Cited by 42 · cited 5×
“The incidence of DPN found in our prospective study is low (0.7% per year) compared with previous studies of people with newly and clinically diagnosed type 2 diabetes (which observed an Table 3—Risk of incident DPN by clinically relevant changes in continuous potential risk factors for incident DPN and by doubling of…”
BackgroundSelf-citationJensen, T. M., Vistisen, D., Fleming, T. H., Nawroth, P. P., Jørgensen, M. E., Lauritzen, T., Sandbæk, A., & Witte, D. R. (2015) · Acta Diabetologica · doi:10.1007/s00592-015-0739-7 · Cited by 9
Self-citation
Cited by
Feldman, E. L., Callaghan, B. C., Pop-Busui, R., Zochodne, D. W., Wright, D. E., Bennett, D. L., Bril, V., Russell, J. W., & Viswanathan, V. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0092-1 · Cited by 1,697
Self-citationSchalkwijk, C. G., & Stehouwer, C. D. A. (2020) · Physiological Reviews · doi:10.1152/physrev.00001.2019 · Cited by 622
Selvarajah, D., Kar, D., Khunti, K., Davies, M. J., Scott, A. R., Walker, J., & Tesfaye, S. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30081-6 · Cited by 556
Pathogenesis, diagnosis and clinical management of diabetic sensorimotor peripheral neuropathy
Sloan, G., Selvarajah, D., & Tesfaye, S. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00496-z · Cited by 534
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Metadata
- Authors
- Andersen, S. T., Witte, D. R., Dalsgaard, E.-M., Andersen, H., Nawroth, P., Fleming, T., Jensen, T. M., Finnerup, N. B., Jensen, T. S., Lauritzen, T., Feldman, E. L., Callaghan, B. C., & Charles, M.
- Affiliations
- Aarhus University (DK)
- Aarhus University Hospital (DK)
- University Hospital Heidelberg (DE)
- University of Michigan (US)
- Corresponding author
- Andersen, Signe T.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2018-02-27
- Volume
- 41
- Issue
- 5
- Pages
- 1068-1075
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2790769408
- Cited by
- 248
- References
- 41
- Citations by year
- 2026: 16 · 2025: 38 · 2024: 36 · 2023: 38 · 2022: 28 · 2021: 37 · 2020: 29 · 2019: 17 · 2018: 9
- FWCI
- 15.62
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Site cant be reached (submittedVersion)
- Scopus (Elsevier) (submittedVersion)
- PuSH - Publication Server of Helmholtz Zentrum München (submittedVersion)
- Funders
- Novo Nordisk (Novo Nordisk Foundation Challenge Programme grant)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Peripheral Neuropathies and Disorders
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetic Foot Ulcer Assessment and Management
- Keywords
- diabetic polyneuropathy, type 2 diabetes, risk factors, Michigan Neuropathy Screening Instrument, methylglyoxal, HDL cholesterol, LDL cholesterol, waist circumference, body mass index, age, weight, diabetes screening, primary care, neuropathy prevention, intensive diabetes treatment, cumulative incidence, long-term follow-up
- MeSH terms
- Aged, Denmark, Diabetes Mellitus, Type 2, Diabetic Neuropathies, Female, Follow-Up Studies, Humans, Male, Mass Screening, Middle Aged, Obesity, Primary Health Care, Risk Factors, Cohort Studies, Incidence, Waist Circumference
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.